A method of determining an efficiency of dextran sulfate treatment of a patient suffering from a neurological disease, disorder or condition, said method comprising: determining an amount of at least one biomarker selected from each group of group nos. 1 to 6 in a first biological sample taken from said patient prior to administration of dextran sulfate, or a pharmaceutically acceptable salt thereof, to said patient; determining an amount of said at least one biomarker selected from each group of said group nos. 1 to 6 in a second biological sample taken from said patient following administration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, to said patient; determining, for each biomarker, a difference between said amount of said biomarker in said second biological sample and said amount of said biomarker in said first biological sample; and determining said dextran sulfate treatment to be efficient if said amounts of said biomarkers selected from group nos. 1, 3 and 5 are reduced in said second biological sample relative to said first biological sample and if said amounts of said biomarkers selected from group nos. 2, 4 and 6 are increased in said second biological sample relative to said first biological sample, wherein group no. 1 consists of platelet factor 4 and vav guanine nucleotide exchange factor 3; group no. 2 consists of tumor necrosis factor superfamily member 15 (TNFSF15), interleukin 17B (IL-17B), thymic stromal lymphopoietin (TSLP) and corticotropin releasing hormone; group no. 3 consists of fibroblast growth factor 1 and KIT-ligand (KITLG); group no. 4 consists of brain derived neutrophic factor (BDNF), noggin and heparin binding epidermal growth factor like growth factor (HBEGF); group no. 5 consists of alpha fetoprotein, sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (ATP2A3), solute carrier family 29 member 1 (SLC29A1), solute carrier family 40 member 1 (SLC40A1) and transthyretin; and group no. 6 consists of solute carrier family 1 member 4 (SLC1A4), solute carrier family 7 member 11 (SLC7A11), solute carrier family 16 member 7 (SLC16A7), low density lipoprotein receptor (LDLR) and ATPase phospholipid transporting 8A1 (ATP8A1). determining an amount of at least one biomarker selected from each group of group nos. 1 to 6 in a first biological sample taken from said patient prior to administration of dextran sulfate, or a pharmaceutically acceptable salt thereof, to said patient; determining an amount of said at least one biomarker selected from each group of said group nos. 1 to 6 in a second biological sample taken from said patient following administration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, to said patient; determining, for each biomarker, a difference between said amount of said biomarker in said second biological sample and said amount of said biomarker in said first biological sample; and determining said dextran sulfate treatment to be efficient if said amounts of said biomarkers selected from group nos. 1, 3 and 5 are reduced in said second biological sample relative to said first biological sample and if said amounts of said biomarkers selected from group nos. 2, 4 and 6 are increased in said second biological sample relative to said first biological sample, wherein group no. 1 consists of platelet factor 4 and vav guanine nucleotide exchange factor 3; group no. 2 consists of tumor necrosis factor superfamily member 15 (TNFSF15), interleukin 17B (IL-17B), thymic stromal lymphopoietin (TSLP) and corticotropin releasing hormone; group no. 3 consists of fibroblast growth factor 1 and KIT-ligand (KITLG); group no. 4 consists of brain derived neutrophic factor (BDNF), noggin and heparin binding epidermal growth factor like growth factor (HBEGF); group no. 5 consists of alpha fetoprotein, sarcoplasmic/endoplasmic reticulum calcium ATPase 3 (ATP2A3), solute carrier family 29 member 1 (SLC29A1), solute carrier family 40 member 1 (SLC40A1) and transthyretin; and group no. 6 consists of solute carrier family 1 member 4 (SLC1A4), solute carrier family 7 member 11 (SLC7A11), solute carrier family 16 member 7 (SLC16A7), low density lipoprotein receptor (LDLR) and ATPase phospholipid transporting 8A1 (ATP8A1).